What is Sanofi Consumer Healthcare India Altman Z-Score?
Sanofi Consumer Healthcare IndiaNSE:SANOFICONR +1.34%21 Altman Z-Score is 43.33 as of Jul. 11, 2026, which is 4% below its 10-year median of 45.34. GuruFocus rates NSE:SANOFICONR with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 952 Drug Manufacturers companies, Sanofi Consumer Healthcare India ranks better than 98.74% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 43.85 is strong.
Sanofi Consumer Healthcare India has a Altman Z-Score of 43.33, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Sanofi Consumer Healthcare India's Altman Z-Score or its related term are showing as below:
NSE:SANOFICONR'
s Altman Z-Score Range Over the Past 10 Years
Min: 41 Med: 45.34 Max: 52.22
Current: 43.85
During the past 3 years, Sanofi Consumer Healthcare India's highest Altman Z-Score was 52.22. The lowest was 41.00. And the median was 45.34.
Sanofi Consumer Healthcare India (NSE:SANOFICONR) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi Consumer Healthcare India Altman Z-Score Chart
NSE:SANOFICONR vs LLY, JNJ, ABBV: Altman Z-Score Comparison
For the Drug Manufacturers - General subindustry, Sanofi Consumer Healthcare India's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi Consumer Healthcare India Altman Z-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi Consumer Healthcare India's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Sanofi Consumer Healthcare India's Altman Z-Score falls into.
Sanofi Consumer Healthcare India Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a Altman Z-Score of 43.33 as of Jul. 11, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Sanofi Consumer Healthcare India and its competitors. This is near median its historical median of 45.34. Over the past decade, Sanofi Consumer Healthcare India's Altman Z-Score has ranged from 41.00 to 52.22. According to the industry distribution chart, Sanofi Consumer Healthcare India ranks #12 out of 952 companies in the Drug Manufacturers industry, placing it in the top 1.3%.
Is Sanofi Consumer Healthcare India's Altman Z-Score too high?
Sanofi Consumer Healthcare India's current Altman Z-Score of 43.33 is near median its 10-year median of 45.34. Over the past 10 years, this metric has ranged from a low of 41.00 to a high of 52.22. The Drug Manufacturers industry median Altman Z-Score is 3.27. Sanofi Consumer Healthcare India's value of 43.33 is 1225.1% above this industry median. Based on the distribution chart, Sanofi Consumer Healthcare India ranks #12 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanofi Consumer Healthcare India has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi Consumer Healthcare India's Altman Z-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi Consumer Healthcare India ranks #12 out of 952 companies for Altman Z-Score. This places Sanofi Consumer Healthcare India in the top 1% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 3.27. Sanofi Consumer Healthcare India's value of 43.33 is 1225.1% above this benchmark. Historically, Sanofi Consumer Healthcare India's own Altman Z-Score has ranged from 41.00 to 52.22 over the past decade. While the company's 10-year median is 45.34 vs. the industry median of 3.27, Sanofi Consumer Healthcare India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Drug Manufacturers company?
The median Altman Z-Score among Drug Manufacturers companies is 3.27, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi Consumer Healthcare India's current Altman Z-Score of 43.33 is 1225.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Sanofi Consumer Healthcare India and its competitors. For the Drug Manufacturers industry, the median Altman Z-Score is 3.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi Consumer Healthcare India's current Altman Z-Score is 43.33, which is near median its own 10-year median of 45.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi Consumer Healthcare India stock overvalued right now?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a current Altman Z-Score of 43.33. The current Altman Z-Score is 43.33, which is near median its 10-year median of 45.34 and 1225.1% above the Drug Manufacturers industry median of 3.27. Sanofi Consumer Healthcare India's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Sanofi Consumer Healthcare India (NSE:SANOFICONR), the current Altman Z-Score is 43.33 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sanofi Consumer Healthcare India Business Description
Sanofi Consumer Healthcare India Ltd is mainly engaged in the business of manufacturing and trading of drugs and pharmaceutical products. The Company also has various independent contract/third-party manufacturers based across the country and provides business support services to its group entity in India. Its products include Allergy Relief (Allegra), Pain Care (Combiflam), and Physical Wellness (DePURA). The Company sells its products in India through independent distributors and outside India. Its operations are limited to one segment, namely Pharmaceutical Business. The Company operates in India, which generates the maximum revenue, and Outside India.
21GF Score
Get the complete analysis for NSE:SANOFICONR
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SANOFICONR has been successfully added to your 
